

John G Clohessy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/89490/publications.pdf>

Version: 2024-02-01

57
papers

4,798
citations

136940

32
h-index

161844

54
g-index

62
all docs

62
docs citations

62
times ranked

9333
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic ablation of <i>FASN</i> attenuates the invasive potential of prostate cancer driven by <i>Pten</i> loss. <i>Journal of Pathology</i> , 2021, 253, 292-303.	4.5	13
2	Dual DNA and protein tagging of open chromatin unveils dynamics of epigenomic landscapes in leukemia. <i>Nature Methods</i> , 2021, 18, 293-302.	19.0	9
3	Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer. <i>Communications Biology</i> , 2021, 4, 370.	4.4	12
4	NF- κ B Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants. <i>Molecular Cancer Research</i> , 2021, 19, 1137-1145.	3.4	9
5	Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. <i>Cell</i> , 2021, 184, 4753-4771.e27.	28.9	99
6	Optimized RNA-targeting CRISPR/Cas13d technology outperforms shRNA in identifying functional circRNAs. <i>Genome Biology</i> , 2021, 22, 41.	8.8	75
7	Cabozantinib Unlocks Efficient <i>In Vivo</i> Targeted Delivery of Neutrophil-Loaded Nanoparticles into Murine Prostate Tumors. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 438-449.	4.1	10
8	Synergism between CAR-T Cells and a Personalized Tumor Vaccine in Hematological Malignancies. <i>Blood</i> , 2021, 138, 737-737.	1.4	0
9	WWP1 inactivation enhances efficacy of PI3K inhibitors while suppressing their toxicities in breast cancer models. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	7
10	The Tug1 lncRNA locus is essential for male fertility. <i>Genome Biology</i> , 2020, 21, 237.	8.8	61
11	Targeting microtubule sensitizes drug resistant lung cancer cells to lysosomal pathway inhibitors. <i>Theranostics</i> , 2020, 10, 2727-2743.	10.0	5
12	PDX-derived organoids model in vivo drug response and secrete biomarkers. <i>JCI Insight</i> , 2020, 5, .	5.0	66
13	CAV1 - GLUT3 signaling is important for cellular energy and can be targeted by Atorvastatin in Non-Small Cell Lung Cancer. <i>Theranostics</i> , 2019, 9, 6157-6174.	10.0	32
14	Intragenic antagonistic roles of protein and circRNA in tumorigenesis. <i>Cell Research</i> , 2019, 29, 628-640.	12.0	121
15	Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway. <i>Science</i> , 2019, 364, .	12.6	194
16	Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy. <i>Cell Research</i> , 2019, 29, 446-459.	12.0	32
17	Germline NPM1 mutations lead to altered rRNA 2'-O-methylation and cause dyskeratosis congenita. <i>Nature Genetics</i> , 2019, 51, 1518-1529.	21.4	84
18	An Integrated Genome-wide CRISPRa Approach to Functionalize lncRNAs in Drug Resistance. <i>Cell</i> , 2018, 173, 649-664.e20.	28.9	238

#	ARTICLE	IF	CITATIONS
19	Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non-small cell lung cancer. <i>EMBO Molecular Medicine</i> , 2018, 10, .	6.9	109
20	Deregulated PP1 \pm phosphatase activity towards MAPK activation is antagonized by a tumor suppressive failsafe mechanism. <i>Nature Communications</i> , 2018, 9, 159.	12.8	39
21	An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. <i>Nature Genetics</i> , 2018, 50, 206-218.	21.4	229
22	Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms. <i>Nature Medicine</i> , 2018, 24, 165-175.	30.7	137
23	The Mouse Hospital and Its Integration in Ultra-Precision Approaches to Cancer Care. <i>Frontiers in Oncology</i> , 2018, 8, 340.	2.8	20
24	Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGF β 1 Axis. <i>Clinical Cancer Research</i> , 2018, 24, 6078-6097.	7.0	43
25	Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity. <i>Cancer Discovery</i> , 2017, 7, 750-765.	9.4	112
26	Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes <i>PTEN/TP53</i> -Deficient Prostate Cancer to Radiation. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1279-1289.	4.1	37
27	SPAR, a lncRNA encoded mTORC1 inhibitor. <i>Cell Cycle</i> , 2017, 16, 815-816.	2.6	22
28	mTORC1 and muscle regeneration are regulated by the LINC00961-encoded SPAR polypeptide. <i>Nature</i> , 2017, 541, 228-232.	27.8	503
29	Stress from Nucleotide Depletion Activates the Transcriptional Regulator HEXIM1 to Suppress Melanoma. <i>Molecular Cell</i> , 2016, 62, 34-46.	9.7	71
30	The pleiotropic role of non-coding genes in development and cancer. <i>Current Opinion in Cell Biology</i> , 2016, 43, 104-113.	5.4	19
31	<i>In Vivo</i> Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K \rightarrow AKT Signaling at Endosomes. <i>Cancer Discovery</i> , 2015, 5, 740-751.	9.4	86
32	Mouse hospital and co-clinical trial project \rightarrow from bench to bedside. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 491-498.	27.6	109
33	Of Model Pets and Cancer Models: An Introduction to Mouse Models of Cancer. <i>Cold Spring Harbor Protocols</i> , 2014, 2014, pdb.top069757.	0.3	13
34	NPMc $^{+}$ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human disease. <i>Experimental Hematology</i> , 2014, 42, 101-113.e5.	0.4	32
35	Role of BRAFV600E in the First Preclinical Model of Multifocal Infiltrating Myopericytoma Development and Microenvironment. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	31
36	Vulnerabilities of <i>PTEN</i> \rightarrow <i>TP53</i> -Deficient Prostate Cancers to Compound PARP \rightarrow PI3K Inhibition. <i>Cancer Discovery</i> , 2014, 4, 896-904.	9.4	88

#	ARTICLE	IF	CITATIONS
37	hnRNP K Overexpression Synergizes with Mutant NPM1 to Drive Acute Myeloid Leukemia Progression. Blood, 2014, 124, 2382-2382.	1.4	1
38	Role of aberrant PI3K pathway activation in gallbladder tumorigenesis. Oncotarget, 2014, 5, 894-900.	1.8	47
39	Hematological Malignancies and Premalignant Conditions. , 2014, , 467-486.		1
40	Characterization and Analysis of the Composition and Dynamics of the Mammalian Riboproteome. Cell Reports, 2013, 4, 1276-1287.	6.4	50
41	A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nature Genetics, 2013, 45, 747-755.	21.4	138
42	Infrastructure Needs for Translational Integration of Mouse and Human Trials. Cold Spring Harbor Protocols, 2013, 2013, pdb.top078782-pdb.top078782.	0.3	8
43	The RNA Binding Protein ESRP1 Fine-Tunes the Expression of Pluripotency-Related Factors in Mouse Embryonic Stem Cells. PLoS ONE, 2013, 8, e72300.	2.5	39
44	Co-Expression Of The MUC1 Oncoprotein and CD34 On Primary Myeloma Bone Marrow Cells Identifies a Population With Myeloma Initiating Potential. Blood, 2013, 122, 127-127.	1.4	0
45	Found in translation of mTOR signaling. Cell Research, 2012, 22, 1315-1318.	12.0	12
46	Pro-senescence therapy for cancer treatment. Nature Reviews Cancer, 2011, 11, 503-511.	28.4	400
47	Differential Expression of S6K2 Dictates Tissue-Specific Requirement for S6K1 in Mediating Aberrant mTORC1 Signaling and Tumorigenesis. Cancer Research, 2011, 71, 3669-3675.	0.9	19
48	The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model. Blood, 2010, 115, 3341-3345.	1.4	82
49	Subtle variations in Pten dose determine cancer susceptibility. Nature Genetics, 2010, 42, 454-458.	21.4	506
50	A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. Journal of Clinical Investigation, 2010, 120, 681-693.	8.2	290
51	The Role of Nucleophosmin In Hematopoietic Stem Cells and the Pathogenesis of Myelodysplastic Syndrome. Blood, 2010, 116, 95-95.	1.4	5
52	Î²-tting on p63 as a Metastatic Suppressor. Cell, 2009, 137, 28-30.	28.9	21
53	Differential Requirement of mTOR in Postmitotic Tissues and Tumorigenesis. Science Signaling, 2009, 2, ra2.	3.6	64
54	Nucleophosmin Is Required for Macrophage Function and Maturation.. Blood, 2009, 114, 238-238.	1.4	1

#	ARTICLE	IF	CITATIONS
55	Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse. Blood, 2008, 111, 3859-3862.	1.4	120
56	Mcl-1 Interacts with Truncated Bid and Inhibits Its Induction of Cytochrome c Release and Its Role in Receptor-mediated Apoptosis. Journal of Biological Chemistry, 2006, 281, 5750-5759.	3.4	155
57	Characterisation of Mcl-1 cleavage during apoptosis of haematopoietic cells. British Journal of Haematology, 2004, 125, 655-665.	2.5	69